Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Wave Life Sciences Ltd., a biotechnology company focused on RNA medicines, announced it will host a live webcast and conference call on May 8, 2025, at 8:30 a.m. ET to discuss its first quarter 2025 ...

CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, today announced it will release its financial results for the second quarter of fiscal year ...

D-Wave Quantum Inc. (NYSE:QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, will release its financial results for the third quarter of fiscal year 2025 ended September ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, ...